DIABETES PREVENTION TRIAL--TYPE I DIABETES

这是一个筛查高危患者的多中心方案。 成为I型糖尿病患者，并试图通过干预治疗 预防糖尿病的发展。这在最近已经成为可能。 使用胰岛细胞自身抗体(ICA)识别患有 在未来5年内发展为IDDM的可能性为50%。主要 IDDM患者的亲属患糖尿病的风险增加10倍 ICA和这是这项试验的目标群体。病人 哪些人被归类为IDDM的中危或高危 将提供两种随机干预方案中的一种。那些 高危类别的患者(超过50% 在未来5年内开发IDDM)将随机提供 不治疗与每日皮下注射长效阿司匹林的对比试验 代理胰岛素。

This is a multi-centered protocol to screen for patients at high risk of becoming type I diabetics, and to intervene with treatment to attempt to prevent the development of diabetes. It has recently become possible using islet cell autoantibodies (ICA) to identify individuals who have a 50 percent chance of developing IDDM within the next 5 years. Primary relatives of patients with IDDM have a tenfold increased risk of having ICA and this is the group that will be targeted in this trial. Patients who are classified as intermediate risk or high risk for developing IDDM will be offered one of two randomized intervention protocols. Those patients in the high risk category (greater than 50 percent of developing IDDM over the next 5 years) will be offered a randomized trial of no treatment versus daily subcutaneous injections of long- acting insulin.